Aldeyra Therapeutics (ALDX) EBT (2013 - 2026)

Aldeyra Therapeutics (ALDX) has reported EBT for 14 consecutive years, with -$5.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT rose 44.2% year-over-year to -$5.5 million; the trailing twelve-month figure through Jun 2026 stood at -$23.1 million (up 54.46% YoY), and the FY2025 full-year result was -$33.8 million, up 39.4% from the prior year.
• EBT declined to -$5.5 million in Q2 2026 per ALDX's latest filing, from -$3.5 million in the prior quarter.
• Across five years, EBT topped out at -$3.5 million in Q1 2026 and bottomed at -$17.8 million in Q2 2022.
• Historically, EBT has averaged -$11.0 million across 5 years, with a median of -$9.8 million in 2025.
• The sharpest annual moves came in 2024 and 2026: EBT sank 232.61% in 2024, then soared 65.23% in 2026.
• Over 5 years, EBT stood at -$12.9 million in 2022, then surged by 63.16% to -$4.8 million in 2023, then tumbled by 232.61% to -$15.8 million in 2024, then jumped by 59.13% to -$6.5 million in 2025, then grew by 15.65% to -$5.5 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$5.5 million, -$3.5 million, and -$6.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.